Cargando…

P-values, survival analyses and phase II trials.

Detalles Bibliográficos
Autor principal:	Fayers, P.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1969438/ https://www.ncbi.nlm.nih.gov/pubmed/8043122

Ejemplares similares

Hepatic profile analyses of tipranavir in Phase II and III clinical trials
por: Mikl, Jaromir, et al.
Publicado: (2009)

Prognostic value of the S-phase fraction of breast cancer.
por: Remvikos, Y.
Publicado: (1993)

Design of Phase II cancer trials evaluating survival probabilities
por: Case, L Douglas, et al.
Publicado: (2003)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023)

A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer
por: Solheim, Tora S., et al.
Publicado: (2017)

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses
por: Wetzler, M, et al.
Publicado: (2015)

Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials
por: Kotecki, Nuria, et al.
Publicado: (2012)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib
por: Griebsch, Ingolf, et al.
Publicado: (2014)

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial
por: Kubasch, A. S., et al.
Publicado: (2023)

Concerns about subgroup analyses and reason for stopping remdesivir trial
por: Vijayaraghavan, Bharath Kumar Tirupakuzhi
Publicado: (2022)

Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials
por: Yada, Shinjo, et al.
Publicado: (2017)

Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial
por: Gomez-Ruiz, Victoria, et al.
Publicado: (2023)

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial
por: McMahon, James H., et al.
Publicado: (2020)

Comment On: Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma
por: Liu, Zhi-Peng, et al.
Publicado: (2023)

Patient survival after D (1) and D (2) resections for gastric cancer: long-term results of the MRC randomized surgical trial
por: Cuschieri, A, et al.
Publicado: (1999)

Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas
por: Levin, Victor A, et al.
Publicado: (2007)

ASN guidelines on P values
por: Verhoef, Hans, et al.
Publicado: (2022)

IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma
por: Pirosa, Maria Cristina, et al.
Publicado: (2022)

E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2023)

B Physics analyses for the Phase-II Upgrade Technical Proposal
por: CMS Collaboration
Publicado: (2015)

Trans‐omic analyses identified novel prognostic biomarkers for colorectal cancer survival
por: Liu, Chanjuan, et al.
Publicado: (2023)

The authors respond to “Concerns about subgroup analyses and reason for stopping remdesivir trial”
por: Murthy, Srinivas
Publicado: (2022)

The value of survival analyses for evidence-based rural medical workforce planning
por: Russell, Deborah J, et al.
Publicado: (2013)

Letter Regarding “Moderating Effects in Randomized Trials—Interpreting the P Value, Confidence Intervals, and Hazard Ratios”
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022)

Meta-analyses of TCE carcinogenicity.
por: Borak, J, et al.
Publicado: (2000)

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2017)

Misleading analyses.
por: Peto, R.
Publicado: (1978)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
por: Wadsley, Jon, et al.
Publicado: (2023)

Misleading P-Value:Do You Recognise It?
por: Pitak-Arnnop, Poramate, et al.
Publicado: (2010)

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
por: Bug, G, et al.
Publicado: (2017)

A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial
por: Moreno-González, G., et al.
Publicado: (2021)

Nonsignificant P values cannot prove null hypothesis: Absence of evidence is not evidence of absence
por: Jaykaran,, et al.
Publicado: (2011)

A significant p value is not equivalent to the superiority of one test index over another
por: Ji, Qiaoying, et al.
Publicado: (2019)

Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
por: Suleiman, Ahmed A., et al.
Publicado: (2018)

HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
por: Stevens, Wendy B.C., et al.
Publicado: (2020)

COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
por: Welén, Karin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ru9puhgva6uj7j673928h3h2lp